Glaxo-Novartis JV ‘On Track’ To Launch; J&J ‘Well Through’ Most Of OTC Remediation
This article was originally published in The Tan Sheet
Executive Summary
Glaxo’s consumer product sales will be around 25% of the $40 billion total annual revenues the firm projects following the closure of its Novartis agreement. J&J CEO Alex Gorsky sees light at the end of the tunnel for remediation of the firm’s OTC manufacturing under a consent decree with FDA.
You may also be interested in...
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
While Opening Dietary Ingredient Portfolio Wider, DuPont Opens Door On Online Supply Store
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: